Background Middle-aged men seem to be particularly susceptible to adverse cardiovascular effects of endurance exercise. The ...

Edgewise announces completion of EDG-7500 CIRRUS-HCM phase 2 parts B & C and favourable interim safety results from the ongoing part D study in hypertrophic cardiomyopathy ...

Now Scherr and his colleagues have found that, while the heart shows some evidence of impairment right after a race, it quickly heals. And there are no long-term negative effects after 10 years of ...

Edgewise Therapeutics, Inc., (Nasdaq: EWTX), today announced positive updates from the ongoing CIRRUS-HCM, Phase 2 clinical ...

Edgewise's EDG-7500 showed clinical activity and a favorable safety profile in Phase 2 trial for hypertrophic cardiomyopathy.

"HCM is a heart muscle disease associated with a significant symptom burden. This approval of a new drug, Myqorzo, represents ...

Discover why Edgewise Therapeutics, Inc. is rated Buy amid strong trial data, unique HCM treatment, and major 2026 catalysts. Click for this EWTX update.

Phase II ARCHER trial showed a significant reduction in left ventricular (LV) mass (p=0.0117) and improvements in multiple key cardiac MRI (CMR) measures of structural heart recovery in patients with ...

MYQORZO, a Cardiac Myosin Inhibitor, Directly Addresses Underlying Hypercontractility Associated with Obstructive HCMFDA Approval Based on ...

From a global regulatory perspective, Cytokinetics is expanding its footprint rapidly. The drug received approval in China on ...

The existing clinical data supporting safety and efficacy of CardiAMP Cell Therapy for HFrEF is subject to ongoing regulatory discussions in Japan and the United States. The compilation includes data ...